The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- Author
- JAMNITSKI, Anna1 ; BARTELDS, Geertje M1 ; NURMOHAMED, Michael T1 2 ; VAN SCHOUWENBURG, Pauline A3 ; VAN SCHAARDENBURG, Dirkjan1 2 ; STAPEL, Steven O3 ; DIJKMANS, Ben A. C1 2 ; AARDEN, Lucien3 ; JAN WOLBINK, Gerrit1 3
[1] Jan van Breemen Institute, Amsterdam, Netherlands
[2] VU University Medical Centre, Amsterdam, Netherlands
[3] Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands - Source
Annals of the rheumatic diseases. 2011, Vol 70, Num 2, pp 284-288, 5 p ; ref : 26 ref
- CODEN
- ARDIAO
- ISSN
- 0003-4967
- Scientific domain
- Rheumatology
- Publisher
- BMJ Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adalimumab Anticorps Antipsoriasique Etanercept Immunodépresseur Immunomodulateur Infliximab Pronostic Rhumatologie
- Keyword (en)
- Adalimumab Antibody Antipsoriatic agent Etanercept Immunosuppressive agent Immunomodulator Infliximab Prognosis Rheumatology
- Keyword (es)
- Adalimumab Anticuerpo Antipsoriásico Etanercept Inmunodepresor Inmunomodulador Infliximab Pronóstico Reumatología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system
- Discipline
- Osteoarticular pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 23733827
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1136/ard.2010.135111 
https://dx.doi.org/10.1136/ard.2010.135111
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"284\";s:8:\"\u0000*\u0000epage\";s:3:\"288\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"JAMNITSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Anna\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:19:\"BARTELDS, Geertje M\";i:1;s:21:\"NURMOHAMED, Michael T\";i:2;s:27:\"VAN SCHOUWENBURG, Pauline A\";i:3;s:26:\"VAN SCHAARDENBURG, Dirkjan\";i:4;s:16:\"STAPEL, Steven O\";i:5;s:18:\"DIJKMANS, Ben A. C\";i:6;s:14:\"AARDEN, Lucien\";i:7;s:19:\"JAN WOLBINK, Gerrit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"284\";s:8:\"\u0000*\u0000epage\";s:3:\"288\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"JAMNITSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Anna\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:19:\"BARTELDS, Geertje M\";i:1;s:21:\"NURMOHAMED, Michael T\";i:2;s:27:\"VAN SCHOUWENBURG, Pauline A\";i:3;s:26:\"VAN SCHAARDENBURG, Dirkjan\";i:4;s:16:\"STAPEL, Steven O\";i:5;s:18:\"DIJKMANS, Ben A. C\";i:6;s:14:\"AARDEN, Lucien\";i:7;s:19:\"JAN WOLBINK, Gerrit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"284\";s:8:\"\u0000*\u0000epage\";s:3:\"288\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"JAMNITSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Anna\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:19:\"BARTELDS, Geertje M\";i:1;s:21:\"NURMOHAMED, Michael T\";i:2;s:27:\"VAN SCHOUWENBURG, Pauline A\";i:3;s:26:\"VAN SCHAARDENBURG, Dirkjan\";i:4;s:16:\"STAPEL, Steven O\";i:5;s:18:\"DIJKMANS, Ben A. C\";i:6;s:14:\"AARDEN, Lucien\";i:7;s:19:\"JAN WOLBINK, Gerrit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"284\";s:8:\"\u0000*\u0000epage\";s:3:\"288\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"JAMNITSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Anna\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:19:\"BARTELDS, Geertje M\";i:1;s:21:\"NURMOHAMED, Michael T\";i:2;s:27:\"VAN SCHOUWENBURG, Pauline A\";i:3;s:26:\"VAN SCHAARDENBURG, Dirkjan\";i:4;s:16:\"STAPEL, Steven O\";i:5;s:18:\"DIJKMANS, Ben A. C\";i:6;s:14:\"AARDEN, Lucien\";i:7;s:19:\"JAN WOLBINK, Gerrit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.135111\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"284\";s:8:\"\u0000*\u0000epage\";s:3:\"288\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"JAMNITSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Anna\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:19:\"BARTELDS, Geertje M\";i:1;s:21:\"NURMOHAMED, Michael T\";i:2;s:27:\"VAN SCHOUWENBURG, Pauline A\";i:3;s:26:\"VAN SCHAARDENBURG, Dirkjan\";i:4;s:16:\"STAPEL, Steven O\";i:5;s:18:\"DIJKMANS, Ben A. C\";i:6;s:14:\"AARDEN, Lucien\";i:7;s:19:\"JAN WOLBINK, Gerrit\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
